Compass Therapeutics (NASDAQ:CMPX) Rating Increased to Outperform at Leerink Partners

Compass Therapeutics (NASDAQ:CMPX) was upgraded by equities research analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a $6.00 price objective on the stock, up from their prior price objective of $4.00. Leerink Partners’ target price suggests a potential upside of 167.86% from the stock’s current price.

Several other equities research analysts have also issued reports on CMPX. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Jefferies Financial Group raised their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Guggenheim assumed coverage on shares of Compass Therapeutics in a research note on Monday, February 24th. They issued a “buy” rating and a $12.00 target price for the company. Finally, D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $11.63.

Compass Therapeutics Stock Up 17.9 %

Shares of Compass Therapeutics stock opened at $2.24 on Wednesday. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08. The stock has a market capitalization of $309.75 million, a P/E ratio of -6.05 and a beta of 1.19. The stock has a 50 day moving average price of $2.83 and a two-hundred day moving average price of $2.11.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Sell-side analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently made changes to their positions in the company. Barclays PLC raised its holdings in Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after buying an additional 356,352 shares during the period. Geode Capital Management LLC raised its stake in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after buying an additional 19,095 shares during the last quarter. Bleakley Financial Group LLC lifted its holdings in Compass Therapeutics by 250.7% in the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock valued at $58,000 after buying an additional 28,589 shares during the period. Finally, Intech Investment Management LLC boosted its stake in Compass Therapeutics by 218.7% in the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock valued at $75,000 after acquiring an additional 35,632 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.